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he present study was conducted to evaluate the utilization of Clark’s, Salisbury and Penna’s rules and the Body Surface
Area (BSA) formula for calculation of pediatric drug dosage, as well as their reliability and viability in the clinical use. These
rules are frequently cited in the literature, but much controversy still exists with regards to their use. The pediatric drug dosage
was calculated by utilization of the aforementioned rules and using the drugs Paracetamol, Dipyrone, Diclofenac Potassium,
Nimesulide, Amoxicillin and Erythromycin, widely employed in Pediatric Dentistry. Weight and body surface areas were
considered of children with ages between 1 and 12 years old as well as the dosage for the adult. The pediatric dosages achieved
were compared to the predetermined dosages in mg kg-1 herein-named standard dosages. The results were submitted to the
parametric test ANOVA and to the Tukey test (p<0,05). The antibiotics and Diclofenac provides acceptable utilization of the
rules in pediatric dentistry, however for the Dipyrone, the dosages obtained by the rules suggest their clinical ineffectiveness.
For the Paracetamol, the Penna’s rule and the BSA formula should not be clinically employed, especially for children between
1 and 5 years old, once such dosages were much close to the hepatotoxic dosage of the drug. It can be concluded that the use
of the rules for safe calculation of the pediatric drug dosage is possible and it depends on the used drug and age group.
Uniterms: Pediatric dentistry, Oral administration, posology.
  presente estudo foi realizado com a finalidade de avaliar as fórmulas de Clark, Salisbury, Área da Superfície Corpórea
(ASC) e Penna, quanto a sua confiabilidade e viabilidade de uso clínico para o cálculo de doses medicamentosas infantis, uma
vez que tais fórmulas são freqüentemente citadas na literatura, mas muita controvérsia ainda existe com relação ao seu uso. As
doses infantis foram calculadas utilizando as  fórmulas descritas e os medicamentos Paracetamol, Dipirona, Diclofenaco de
Potássio, Nimesulida, Amoxicilina e Eritromicina, largamente usados na clínica odontopediátrica. Foram considerados parâmetros
como o peso e área da superfície corpórea de crianças com idades entre 1 e 12 anos e a dose para o adulto. As doses obtidas
foram comparadas às doses em mg/kg consideradas como padrão de referência para os medicamentos. Os resultados foram
submetidos ao teste paramétrico ANOVA e de Tukey (P<0,05). Os antibióticos e o Diclofenaco propiciam utilização aceitável
das fórmulas na Odontopediatria, porém para a Dipirona, as doses obtidas pelas fórmulas sugerem ineficácia clínica. Para o
Paracetamol, o uso clínico das fórmulas de Penna e da ASC para crianças entre 1 a 5 anos é contra-indicado, uma vez que as
doses obtidas com tais fórmulas aproximaram-se muito das doses hepatotóxicas do medicamento. Pode-se concluir que o uso
das fórmulas para o cálculo seguro de doses infantis é viável, dependendo do medicamento utilizado e da faixa etária.
Unitermos: Odontopediatria; Administração oral de medicamentos, posologia.
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INTRODUCTION
The most important aspect for selection of a drug and
establishment of the proper pediatric dosage is the
acknowledgment that the pediatric patient is not just a small
adult. Newborns, children and adolescents have different
physiological, pharmacokinetic and pharmacodynamic
parameters compared to adults. The differences are mainly
related to the changes occurring during growth and
maturation and require individual dosages. Thus, guidelines
of specific dosages and useful means for calculation of
pediatric dosages must be developed in order to enhance
the effectiveness and therapeutic limit and prevent serious
adverse effects19.
Two methods are commonly reported as being favorable
for definition of the proper pediatric dosage, namely per
weight and per Body Surface Area. However, such methods
not always yield the same drug dosage, leading to the need
of proper evaluation to determine the ideal situation for each
individual6. Utilization of body weight as a criterion for
evaluation of therapeutic dosages should be employed just
for mean dosages, usually calculated for antibiotics, since
the blood concentrations of the drugs are not proportional
to weight10,20. Dosages based on the body weight are
believed to be insufficient for the achievement of proper
serum concentration of most drugs, being the body surface
the most valid basis for dosage, since it is related to some
physiological functions that account for the differences in
pharmacokinetics in patients of different ages2,13,21. The
effect of drugs is directly related to the blood volume and
metabolism, being the Body Surface Area better for
calculation of the pediatric dosage7. Measurements of the
volume of the fluid compartment and investigations on the
blood concentrations of drugs have good correlation with
the Body Surface Area8.
The Salisbury rule also provides dosages within the safe
range, close to those recommended by the British National
Formulary (BNF), and less prescription mistakes may be
expected with its utilization. This rule is closely related to
the Body Surface Area, as desirable, and has the further
advantage of easier and more reliable calculation8. However,
Marcondes10 suggests better results with utilization of the
rule empirically established by Penna, which follows the
body surface. It is employed at the Children’s Institute (Sao
Paulo, SP, Brazil).
The literature review demonstrates that, even though
there is a tendency to follow an existing criterion or rule for
calculation of the pediatric drug dosage, there are many
divergent opinions. MARTIN, et al.11 states that the rules
employed for calculation of the pediatric drug dosage are
not completely satisfactory. Even though many rules for
dosage have been developed, it is believed that none has
been precise and simple enough for routine use, allowing
correct and effective dosage calculation without complicated
mathematics8. There are several formulas for calculation of
the pediatric drug dosage based on weight, age, Body
Surface Area or height, yet all of them require careful
application14. The age from which the rules for pediatric
drug dosage may be safely employed is hardly known, and
the different rules available for calculation of the pediatric
drug dosage may indicate their fallibility18. According to
Nahata12, selection of the most proper rule for calculation of
pediatric drug dosages should be careful, since specific
pediatric dosages are not available for all drugs. According
to the author, investigations on the clinical effectiveness of
the dosages achieved should be conducted, even for those
rules regarded as the most adequate.
Thus, the present study was performed with a view to
evaluate the reliability and possibility of clinical utilization
of the existing rules, both by specialists and by dental
professionals that occasionally assist children.
MATERIAL AND METHODS
Voluntary children attending the Pediatric Dental Clinic
of the Federal University Center of Alfenas (CEUFE) were
assessed. Evaluation was conducted in the years 2000 and
2001.
A pilot study was performed for definition of the ideal
sample size to allow statistical analysis. Even though 71
children would be enough, the study included 116 children,
divided into three groups according to the age range7.
* Group 1: 31 children in early childhood, aged 1 to 3
years;
* Group 2: 31 preschool children, aged 3 to 5 years;
* Group 3: 54 school children, aged 6 to 12 years.
1 – 1st experimental stage: personal information record of
the children and drugs prescribed to the children.
Data were provided by the parents and included personal
information of the children such as name, birth date, race,
gender and age. Moreover, weight and height of all children
were measured by a single examiner on an anthropometric
scale (Micheletti, CIMAC, Belo Horizonte, MG- Brazil). Such
records were employed for calculation of the Body Surface
Area of each child, using a specific nomogram5.
The names of the drugs previously employed by the
children because of dental treatment were also recorded.
Before interview, the parents signed an informed consent
term after being informed on the objectives, benefits and
discomforts expected during the study.
The study project was assessed and approved by the
Ethics Committee of CEUFE (Protocol #23087.000691/2002-
12).
2 – 2nd experimental stage: utilization of the data for
calculation of the pediatric dosages and statistical analysis.
The weight, height, age and Body Surface Area records
of the children were employed for calculation of the pediatric
drug dosages with utilization of the Clark’s13, Salisbury8 and
Penna’s10 rules and the Body Surface Area (BSA)3. Children
out of the range of normality (weight/height - age) were
excluded from the study. Graphs of weight-height
development were considered for evaluation of the normality
of children of male and female genders in relation to weight
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and height10.
Calculation of the dosages was performed for each child
by utilization of the rules mentioned in Table 1 and frequently
found in the literature. The pediatric dosages achieved were
compared to the predetermined dosages in mg kg-1, herein
named standard dosages, also calculated for each child.
The reference drugs employed in the study were those most
frequently used in the pediatric clinic: the analgesics
Paracetamol (200mg/mL) and Dipyrone (500mg/mL), the anti-
inflammatory drugs Diclofenac Potassium (15mg/mL) and
Nimesulide (50mg/mL); and the antibiotics Amoxicillin
(250mg/5mL) and Erythromycin (250mg/5mL). The parents
during the interview reported these drugs as the most
frequently prescribed by pediatric dentists for elimination
of pain, inflammation and infectious processes of the oral
cavity.
The standard dosages for antibiotics are mentioned in
the literature as minimum and maximum (Table 2). Therefore,
this was taken into account for comparison between the
rules, since the clinically acceptable pediatric dosages
should fall within the minimum and maximum values.
All dosages calculated in the present study were pooled
and evaluated to verify whether there is a difference in the
dosages obtained by utilization of the four rules and the
Rules Description
Clark’s13 Child dosage =  child’s weight (kg) x adult dosage
 70
Children weighing less than 30kg : weight x 2  = % of the adult dosage
Salisbury8
Children weighing more than 30kg : weight + 30  = % of the adult dosage
Body Surface Area (BSA)3 Pediatric dosage =  BSA of the child x adult dosage
1,73 m 2
Penna’s10 Child dosage  =  adult dosage    x         child’s weight
child’s weight  + 30
     2
* m2 = square meter
TABLE 1- Description of the rules employed for calculation of pediatric drug dosage
GENERIC  NAMES ADULT DOSAGES STANDARD DOSAGES FOR CHILDREN*
PARACETAMOL 750mg every 4 hours1 1 drop per kg per dosage every 4 or 6 hours
maximum 5 administrations per day9 maximum 35 drops per dosage and
5 administrations per day4
DIPYRONE 500mg every 4 hours1 1 drop per kg per dosage every 6 hours3
maximum 5 administrations per day9
DICLOFENAC 50mg every 8 hours1 1 drop per kg per dosage1
POTASSIUM Every 8 or 12 hours4
NIMESULIDE 100mg every 12 hours 1 drop per kg per dosage every 12 hours4
up to 200mg every 12 hours4
AMOXICILLIN 500mg every 8 hours1 20-50mg/kg/day every 8 hours3
ERYTHROMYCIN 500mg every 6 hours13 30-50mg/kg/day every 6 hours / maximum 4g/day15
* As determined by the manufacturer
TABLE 2- Main drugs employed in Pediatric Dentistry and their respective dosages for adults and children
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standard dosage (mg kg-1), even for the pediatric patient.
Moreover, the statistical significance was calculated, and
the possible clinical significance of the differences found
was discussed, since the dosages achieved by application
of the rules were not clinically tested so far. Determination
of the viability of the rules was based on the statistical data.
The data were submitted to the parametric test of analysis
of variance (ANOVA) and to the Tukey test at a significance
level of 5% (P<0.05), by means of the Statgraphics
Statistical Graphics System software, version 7.0. The mean
dosages obtained by the rules were compared for each drug
and for each study group, for a better understanding of the
outcomes.
RESULTS
1- Clark’s rule
The Clark dosages were not statistically significantly
different from the standard dosages (P>0.05) for the drugs
Paracetamol, Amoxicillin (20mg/kg/day) and Erythromycin
(30mg/kg/day), for the three study groups.
2- Salisbury rule
In the three study groups and for all drugs employed,
the Salisbury dosages displayed statistically significant
differences compared to the standard dosages (P<0.05).
However, no statistically significant difference was found
between the Salisbury and the BSA dosages (P>0.05) for
any drug evaluated in Group 3.
3- Body Surface Area (BSA) and Penna’s rule
Both formulas displayed the same outcomes compared
to the standard dosages. For Nimesulide and Erythromycin
(50mg/kg/day) in Groups 1 and 2, the BSA and Penna
dosages were not statistically significantly different from
the standard dosages (P>0.05). All drugs in Group 3 revealed
statistically significant differences when the BSA and Penna
dosages were compared to the standard dosages (P<0.05).
DISCUSSION
1- Clark’s rule
From a clinical standpoint, the Dipyrone dosages
obtained by the Clark’s rule and employed for pain control
in the pediatric patient would be much below the therapeutic
standard dosage recommended in the 3 study groups (Figure
1). The clinical effect desired may not be achieved with such
dosages, yet further investigations with clinical tests should
be performed.
As regards to Amoxicillin (50mg/kg/day) and
Erythromycin (50mg/kg/day), clinical infection control might
be obtained with the Clark dosages, since minimum effective
dosages are accepted for these antibiotics (Amoxicillin –
20mg/kg/day; and Erythromycin – 30mg/kg/day).
Concerning the anti-inflammatory drugs employed in the
present study, incoherent outcomes were found upon
comparison of the Clark and standard dosages. Further
investigations would be required to check maintenance of
the clinical effects with the statistically different Clark
dosages for both Nimesulide and Diclofenac. However, it
may be observed that the Diclofenac dosages were not
above the dosage of 2mg kg-1,15 regarded as the maximum
ideal dosage, for Groups 1 and 2; nor were they higher than
50mg, which is the adult dosage recommended, for Group 3.
2- Salisbury rule
Evaluation of the drugs Paracetamol and Diclofenac in
the 3 study groups reveals a statistically significant
difference between the values achieved for the Salisbury
and standard dosages. However, the Diclofenac dosages
were not higher than 2mg kg-1,15, for Groups 1 and 2; nor
were they higher than 50mg for Group 3 (Figure 2). Also, the
Paracetamol dosages were not higher than the maximum
non-hepatotoxic standard dosage accepted for this drug,
namely 90mg/kg/day6. For more security, additional studies
should be conducted to verify maintenance of the clinical
effects with the dosages found without the risk of
exacerbated or toxic side effects to the pediatric patient.
The behavior of Dipyrone and Nimesulide was similar in
all three studies groups. Clinically, the Salisbury dosages
for Dipyrone and Nimesulide would be below the therapeutic
standard dosage recommended therefore, such dosages
might not yield a satisfactory clinical response.
As regards to Amoxicillin (Figure 3) and Erythromycin, a
similar behavior was observed for all three studies groups.
The Salisbury dosages of these drugs might be employed
for infection control in the pediatric patient, since they would
be within the therapeutic dosages recommended, i.e. within
the minimum and maximum effective standard dosages of
FIGURE 1- Mean Dipyrone dosages for the rules evaluated
in the three study groups
FIGURE 2- Mean Diclofenac dosages for the rules evaluated
in the three study groups
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these antibiotics.
According to Lack and Stuart-Taylor8, the Salisbury rule
allows easy calculations, and ten-year investigations have
revealed no clinical evidence of improper dosages. In the
authors’ opinion, such rule may be employed instead of the
BSA in specific situations, since in accordance with Walson,
et al.22 the body surface may be regarded as a better parameter
than weight for determination of drug dosage, even though
it comprises measurements that are hard to obtain.
Comparison between the Salisbury and the BSA dosages in
the present study did not reveal any statistically significant
difference for any drug in Group 3 (P>0.05). The Salisbury
dosages calculated in Groups 1 and 2 were always lower
than the BSA dosages and presented significant differences
for all drugs. These results reveal discordant data compared
to those found by Lack and Stuart-Taylor8, who
demonstrated similar dosages between the Salisbury and
BSA dosages and thus indicate utilization of the first
because of the easier calculation.
3- Body Surface Area (BSA)
Paracetamol, Dipyrone, Diclofenac and the antibiotics
evaluated presented a similar behavior in three groups.
Clinically, the Dipyrone dosages achieved by the BSA
formula that would be employed for pain control in the
pediatric patient are assumed to be much below the
therapeutic standard dosage recommended, not being able
to provide proper clinical response. Paracetamol presented
BSA dosages much above the therapeutic dosage
recommended (Figure 4). Such dosages exceeded or were
much close to the hepatotoxic dosage of the drug, especially
in groups 1 and 2, upon individual comparison of the
children. Verification of the maintenance of the clinical effects
with the dosages found without the risk of exacerbated or
toxic side effects to the pediatric patient is required. As
regards to Diclofenac, the drug dosages obtained by the
BSA formula that would be employed for control of
inflammation in the pediatric patient are higher than the
therapeutic standard dosage recommended and did not
exceed the ideal maximum dosage of 2mg kg-1,15, in groups 1
and 2.
Incoherent outcomes were found for Nimesulide (Figure
5). For Amoxicillin and  Erythromycin (Figure 6). Despite the
statistically significant difference between the standard and
BSA dosages, the antibiotic dosages achieved by the BSA
formula might be effective for clinical infection control, since
they are within the therapeutic dosages recommended.
The results found in the present study for the antibiotics
partially confirm the report of Tavares20, who stated that the
dosages, especially of these drugs, should be calculated on
the basis of the child’s weight. However, it may be observed
that calculation based on the BSA is also acceptable.
According to Robinson and Williams16, these two methods
for dosage calculation are favorable for establishment of
the proper pediatric dosage. The authors confirm the
outcomes found in the present study, highlighting that both
methods not always yield the same drug dosage. However,
they present a different opinion on the present results,
stating that the differences between the dosages achieved
by weight and by the Body Surface Area are larger in
younger children. In the opinion of Rodman17, the pediatric
dosages adjusted by the BSA are substantially higher than
the dosages adjusted by body weight, as observed for the
drugs Paracetamol and Diclofenac in the three study groups.
4- Penna’s rule
Results similar to those obtained by utilization of the
BSA formula were found by application of the Penna’s rule,
FIGURE 3- Mean Amoxicillin dosages for the rules evaluated
in the three study groups
FIGURE 4- Mean Paracetamol dosages for the rules
evaluated in the three study groups
FIGURE 5- Mean Nimesulide dosages for the rules
evaluated in the three study groups
FIGURE 6- Mean Erythromycin dosages for the rules
evaluated in the three study groups
118
ELIAS G P, ANTONIALI C, MARIANO R C
J Appl Oral Sci 2005; 13(1): 10-4
when both were compared to the standard dosage. Such
findings corroborate the report of Marcondes10, who
suggested that the Penna’s rule follow the body surface.
The present study demonstrated that the Penna dosages
were always higher than the BSA dosages, even though
this difference was not statistically significant for some
drugs. Nevertheless, the Penna dosages achieved for
Paracetamol exceeded or were close to the hepatotoxic
dosage of the drug,6 especially in Groups 1 and 2. As regards
to Diclofenac and Dipyrone, the results were similar to those
achieved by the BSA formula. As to the antibiotics, the
Penna dosages were higher than the BSA dosages, yet they
were not statistically different from the maximum standard
dosages recommended for such drugs.
Despite the higher dosages achieved, the Penna’s rule
was quite similar to the BSA formula, with the advantage of
simpler application.
CONCLUSIONS
1- Compared to the standard dosage, for the antibiotics
evaluated, the Clark’s, Salisbury, and Penna’s rules and the
BSA formula allowed the achievement of dosages above
the effective dosage recommended and below the maximum
dosage allowed. It provided acceptable utilization in Pediatric
Dentistry, since there are few reports of toxicity of these
antibiotics.
2- As to Dipyrone, the standard dosages were much
above the dosages obtained by the rules, suggesting their
clinical ineffectiveness (P<0.05).
3- Concerning Diclofenac, the rules might be
satisfactorily applied in the clinics, because the dosages
obtained were above the standard dosage (P<0.05), yet they
were not higher than the maximum pediatric dosage allowed.
4- In relation to Paracetamol, it is believed that the Penna’s
rule and the BSA formula should not be clinically employed,
especially for children in the age range of Groups 1 and 2.
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